Sign up to save your podcasts
Or
Share Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
At AAN Annual Meeting 2026, ADAPT Jr showed efgartigimod alfa delivered durable adolescent gMG improvements, with 80% achieving minimal symptom expression by cycle two and consistent responses.
View all episodes
By TheBrief.HealthAt AAN Annual Meeting 2026, ADAPT Jr showed efgartigimod alfa delivered durable adolescent gMG improvements, with 80% achieving minimal symptom expression by cycle two and consistent responses.